Kibow Biotech, Inc. is pleased to announce that it has been granted an International Patent Cooperation Treaty (PCT) patent from Australia, China and India. The approved patent, "Prebiotic and Probiotic Compositions and their Method of use for Gut-based Therapy," protects the composition and method behind the Company's oral probiotic product formulation (Kibow Biotics(R)) which may significantly reduce concentrations of several nitrogenous waste metabolites that accumulate in renal deficiency. The serial numbers for this patent are: 20022342641 (Australia), ZL 02810078.6 (China) and 1029/MUMNP/2003, 205478 (India). Kibow Biotech has an identical PCT patent pending in Canada, the European Union, Japan, and South Korea.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has received allowance of its patent application in India covering its lead dermatology agent, PH-10, along with a number of related agents. The pending patent covers topical products for treatment of skin diseases such as psoriasis and eczema. Additionally, a range of active compounds are protected, each related to the active ingredient in PH-10.
CEVEC Pharmaceuticals GmbH, the specialist supplier for human expression technologies, today announced that an opposition to a patent owned by Crucell N.V., Leiden, Netherlands, before the European Patent Office was again successful. This is the second time within a year that the Opposition Division of the European Patent Office (EPO) has restricted a patent on Crucell’s PER.C6 cell line.
No comments:
Post a Comment